AndreCMHausmanJFGuerrieroG.Cannabis sativa: the plant of the thousand and one molecules. Front Plant Sci. 2016;7:19. doi:10.3389/fpls.2016.00019
3.
Agriculture Improvement Act, S. 10113, 115th Cong. (2018) or S. 12619, 115th Cong. (2018).
4.
Agriculture Improvement Act of2018, Pub. L. 115-334 (December10, 2018).
5.
Therapeutic Research Center. CBD. Natural Medicines [database]. Updated November13, 2019. Accessed December 15, 2019.
6.
ShannonSLewisNLeeHHughesS.Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23: 18-041. doi:10.7812/TPP/18-041
7.
StanleyCPHindWHTufarelliC, et al. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc Res. 2015;107(4):568-578.
8.
RajeshMMukhopadhyayPBatkaiS, et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol. 2010;56(25): 2115-2125.
9.
National Academies of Sciences, Engineering, and Medicine. The Health Effects of Cannabis and Cannabinoids: Current State of Evidence and Recommendations for Research. The National Academies Press; 2017.
10.
PertweeRG.The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol. 2008;153(2):199-215.
11.
BorowskaMCzarnywojtekASawicka-GutajN, et al. The effects of cannabinoids on the endocrine system. Endokrynol Pol. 2018;69(6):705-719.
12.
JourdanTGodlewskiGKunosG.Endocannabinoid regulation of β-cell functions: implications for glycaemic control and diabetes. Diabetes Obes Metab. 2016;18(6):549-557.
13.
HirschSTamJ.Cannabis: from a plant that modulates feeding behaviors toward developing selective inhibitors of the peripheral endocannabinoid system for the treatment of obesity and metabolic syndrome. Toxins. 2019;11(5):E275.
14.
JadoonKARatcliffeSHBarrettDA, et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care. 2016;39(10):1777-1786.
15.
TothCCJedrzejewskiNMEllisCL, et al. Cannabinoidmediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol Pain. 2010;6:16.
16.
GrudenGBaruttaFKunosG, et al. Role of the endocannabinoid system in diabetes and diabetic complications. Br J Pharmacol. 2016;173(7):1116-1127.
17.
SunSHuFWuJ, et al. Cannabidiol attenuates OGD/ R-induced damage by enhancing mitochondrial bioenergetics and modulating glucose metabolism via pentose-phosphate pathway in hippocampal neurons. Redox Biol. 2017;11: 577-585.
18.
GuindonJHohmannAG.The endocannabinoid system and pain. CNS Neurol Disord Drug Targets. 2009;8(6): 403-421.
19.
SelvarajahDGandhiREmeryCJTesfayeS.Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33(1):128-130. doi:10.2337/dc09-1029
20.
El-RemessyABAl-ShabraweyMKhalifaY, et al. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol. 2006;168(1):235-244.
21.
El-RemessyABRajeshMMukhopadhyayP, et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia. 2011;54(6):1567-1578.
22.
HorvathBMukhopadhyayPHaskoG, et al. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol. 2012;180(2):432-442.
23.
2017 glossary of cannabinoid terms. Published 2017. Accessed December 15, 2019. https://www.cannabinoid clinical.com/themes/custom/cbed/pdf/cannabis-glossaryterms.pdf
